Analysis of the Safety Profile of Direct Oral Anticoagulants Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Deloughery, Emma P. [1 ]
Shatzel, Joseph J. [2 ]
机构：
[1] Mayo Clin, Sch Med, Rochester, MN USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-109818
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2531
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
    Chen, Zepeng
    Li, Ming
    Li, Shuzhen
    Li, Yuxi
    Wu, Junyan
    Qiu, Kaifeng
    Yu, Xiaoxia
    Huang, Lin
    Chen, Guanghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 339 - 342
  • [42] Comparison of hemorrhagic profile among direct acting oral anti-coagulants (DOACs): Risk quantification by using US FDA adverse event reporting system (FAERS)
    Chiranjeevi, Pudi
    Saraswathy, G. R.
    Viswam, Subeesh Kulangara
    Swaroop, Ann Mary
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 593 - 593
  • [43] Using data mining to predict safety actions from FDA adverse event reporting system data
    Hochberg, Alan M.
    Reisinger, Stephanie J.
    Pearson, Ronald K.
    O'Hara, Donald J.
    Hall, Kevin
    [J]. DRUG INFORMATION JOURNAL, 2007, 41 (05): : 633 - 643
  • [44] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
  • [45] Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
    Shuai, Yichun
    Chen, Zhe
    Wan, Qiaoqian
    Wu, Jinzheng
    Wang, Xin
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [46] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Using Data Mining to Predict Safety Actions from FDA Adverse Event Reporting System Data
    Alan M. Hochberg
    Stephanie J. Reisinger
    Ronald K. Pearson
    Donald J. O’Hara
    Kevin Hall
    [J]. Drug information journal : DIJ / Drug Information Association, 2007, 41 : 633 - 643
  • [48] ASSESSMENT OF THE SAFETY OF ONCOLOGY THERAPEUTIC BIOLOGIC DRUGS USING THE US FDA ADVERSE EVENT REPORTING SYSTEM
    Lotfi, K.
    Althobaiti, H.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2020, 23 : S57 - S57
  • [49] Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
    Chang, En
    Shi, Yong-Fang
    Liu, Jin-Feng
    Wei, Wei
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [50] Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system
    Wu, Xiang-Ping
    Lu, Xi-Kui
    Wang, Zhen-Ting
    Huang, Ling
    Cai, Ru-Wen
    Yu, Hui-Min
    Li, Jing-Yang
    Xiao, Jian
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, : 975 - 984
12345